{"transactions":[{"id":1013795,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-10-25T00:00:05.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":20806,"price":0.83,"value":17268.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,878 unvested RSUs."}],"balance_after":41760,"source":{"system":"sec-edgar","filing":"0001893729-25-000003","document":"form4-10242025_081001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000189372925000003/form4-10242025_081001.xml","form_type":"4"}},{"id":1101040,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-06-27T00:00:19.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":4511,"price":4.01,"value":18089.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 28,878 unvested RSUs."}],"balance_after":62566,"source":{"system":"sec-edgar","filing":"0001415889-25-018321","document":"form4-06262025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925018321/form4-06262025_080609.xml","form_type":"4"}},{"id":1122815,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-06-05T00:00:16.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":730,"price":3.74,"value":2730.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 41,159 unvested RSUs."}],"balance_after":67077,"source":{"system":"sec-edgar","filing":"0001415889-25-015681","document":"form4-06042025_080609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925015681/form4-06042025_080609.xml","form_type":"4"}},{"id":1307947,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1307946,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":2021,"price":7.63,"value":15420.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 42,966 unvested RSUs."}],"balance_after":67807,"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1307945,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2025-01-08T01:14:26.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2025, as to 1/3 of the shares underlying the RSUs on January 6, 2026 and as to the final 1/3 of shares underlying the RSUs on January 6, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 42,966 unvested RSUs."}],"balance_after":69828,"source":{"system":"sec-edgar","filing":"0001415889-25-001063","document":"form4-01082025_010122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588925001063/form4-01082025_010122.xml","form_type":"4"}},{"id":1468096,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T00:00:11.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":5158,"price":4.75,"value":24500.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 37,574 unvested RSUs."}],"balance_after":59728,"source":{"system":"sec-edgar","filing":"0001415889-24-018376","document":"form4-06272024_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924018376/form4-06272024_080608.xml","form_type":"4"}},{"id":1495045,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-06-04T00:00:14.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":231,"price":6.09,"value":1406.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 49,855 unvested RSUs."}],"balance_after":64886,"source":{"system":"sec-edgar","filing":"0001415889-24-015225","document":"form4-06032024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924015225/form4-06032024_080610.xml","form_type":"4"}},{"id":1685446,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":20500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1685445,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1385,"price":6.73,"value":9321.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 50,446 unvested RSUs."}],"balance_after":65117,"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1685444,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T21:06:08.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 53,620 unvested RSUs."}],"balance_after":66502,"source":{"system":"sec-edgar","filing":"0001415889-24-000771","document":"form4-01052024_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588924000771/form4-01052024_090101.xml","form_type":"4"}},{"id":1845147,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-24T00:00:29.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":49129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":49129,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":49129},"source":{"system":"sec-edgar","filing":"0001415889-23-010287","document":"form4-06232023_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010287/form4-06232023_080616.xml","form_type":"4"}},{"id":1845146,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-06-24T00:00:29.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,020 unvested RSUs."}],"balance_after":61902,"source":{"system":"sec-edgar","filing":"0001415889-23-010287","document":"form4-06232023_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923010287/form4-06232023_080616.xml","form_type":"4"}},{"id":1869690,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:50.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":648,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,182 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,466 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option was granted on January 3, 2022 and provided for the purchase of up to 1,620 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 432 shares had vested, options to purchase 864 shares had been forfeited and options to purchase up to 324 shares were unvested assuming maximum level of achievement (options to purchase 216 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":648},"source":{"system":"sec-edgar","filing":"0001415889-23-009138","document":"form4-06022023_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009138/form4-06022023_080624.xml","form_type":"4"}},{"id":1869689,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-03T00:00:50.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,182 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,466 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The cancelled option was granted on November 15, 2021 and provided for vesting over four years beginning on the vesting commencement date of November 15, 2021, with 25% of the shares underlying the option vested on November 15, 2022, and an additional 1/48th of the shares underlying the option vesting at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":105,"expiration_date":"2031-11-14","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001415889-23-009138","document":"form4-06022023_080624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009138/form4-06022023_080624.xml","form_type":"4"}},{"id":1869688,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-06-03T00:00:50.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":2648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,182 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,466 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 12,173 unvested RSUs."}],"balance_after":25055,"source":{"system":"sec-edgar","filing":"0001415889-23-009138","document":"form4-06022023_080624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009138/form4-06022023_080624.xml","form_type":"4"}},{"id":1869687,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-06-03T00:00:50.000Z","date":"2023-03-10","kind":"grant","planned":false,"acquired":true,"shares":6977,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the issuer issued 6,977 shares of the Issuer's common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023. This transaction is being reported late due to an inadvertent administrative error."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the issuer issued 6,977 shares of the Issuer's common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023. This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,525 unvested RSUs."}],"balance_after":22407,"source":{"system":"sec-edgar","filing":"0001415889-23-009138","document":"form4-06022023_080624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009138/form4-06022023_080624.xml","form_type":"4"}},{"id":1869686,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-06-03T00:00:50.000Z","date":"2022-02-15","kind":"other","planned":false,"acquired":false,"shares":9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement. This transaction is being reported late due to an inadvertent administrative error."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement. This transaction is being reported late due to an inadvertent administrative error."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,525 unvested RSUs."}],"balance_after":15430,"source":{"system":"sec-edgar","filing":"0001415889-23-009138","document":"form4-06022023_080624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923009138/form4-06022023_080624.xml","form_type":"4"}},{"id":1952147,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T00:00:23.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option."}],"balance_after":432,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":432},"source":{"system":"sec-edgar","filing":"0001415889-23-004978","document":"form4-03152023_080315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923004978/form4-03152023_080315.xml","form_type":"4"}},{"id":2060330,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2023-01-07T01:00:38.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":9525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,525 unvested RSUs and 1,294 shares of the Issuer's common stock issuable to the Reporting Person in connection with the Issuer's acquisition of Combangio, Inc. and which are being held back by the Issuer until February 15, 2023 as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":15439,"source":{"system":"sec-edgar","filing":"0001415889-23-000641","document":"form4-01062023_080127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588923000641/form4-01062023_080127.xml","form_type":"4"}},{"id":2507179,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-18T01:02:56.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 15, 2021 and vests over four years beginning on the vesting commencement date of November 15, 2021, with 25% of the shares underlying the option vesting on November 15, 2022, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":100000,"derivative":{"exercise_price":2.1,"expiration_date":"2031-11-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-21-005280","document":"form4-11172021_051142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005280/form4-11172021_051142.xml","form_type":"4"}},{"id":2507178,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73968,"kind":"person","name":"Kharabi Darius","position":1,"cik":"0001893729","reported_name":"Kharabi Darius","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-11-18T01:02:56.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":295657,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). On November 15, 2021, in connection with the Acquisition, the reporting person acquired the right to receive an aggregate of 295,657 shares of the Issuer's common stock (the \"Shares\") in exchange for 323,415 shares of Combangio's common stock and for an option to purchase 8,754,216 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 295,657 Shares, (i) 230,991 Shares are to be issued by the Issuer to the reporting person on January 3, 2022 and (ii) 64,666 Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 15, 2021, the Issuer acquired Combangio, Inc. (the \"Acquisition\"). On November 15, 2021, in connection with the Acquisition, the reporting person acquired the right to receive an aggregate of 295,657 shares of the Issuer's common stock (the \"Shares\") in exchange for 323,415 shares of Combangio's common stock and for an option to purchase 8,754,216 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 295,657 Shares, (i) 230,991 Shares are to be issued by the Issuer to the reporting person on January 3, 2022 and (ii) 64,666 Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders."}],"balance_after":295657,"source":{"system":"sec-edgar","filing":"0001415889-21-005280","document":"form4-11172021_051142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479419/000141588921005280/form4-11172021_051142.xml","form_type":"4"}}]}